Clinical Benefit of Simtuzumab Inconsistent for Myelofibrosis

Although well tolerated, simtuzumab monotherapy or with ruxolitinib did not confer clinical benefit or reduce bone marrow fibrosis consistently in patients with myelofibrosis by 24 weeks, according to the results from a recently published study. 

 Oncology Nurse Advisor

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.